Sandoz Confirms European Commission Approval of Pyzchiva® (ustekinumab), Further Strengthening Immunology Offering

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in Europe EC approval based on robust development program confirming match to reference medicine in terms of safety, efficacy and quality Sandoz remains committed to accelerating access to potentially life-changing treatments and continues strengthening immunology portfolio [...]